Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial

Peregrine to Report Second Quarter Fiscal Year 2012 Financial Results After Market on December 12, 2011

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

Peregrine to Present at Lazard Healthcare Conference November 15, 2011 at 11:30 AM EST

Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for Bavituximab

Peregrine to Present at JMP Securities Healthcare Conference September 27, 2011 at 12:00 PM EDT

Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy Response

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2012 Financial Results and Recent Developments